SymBio Pharmaceuticals Limited

4582

JP3383050006

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-05 EDT			5-day change	1st Jan Change
181 ^JPY	+4.02%		+9.70%	-26.72%

05-07	Symbio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2024	CI
04-19	SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	CI

Symbio Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year Ending December 30, 2020

November 10, 2020 at 01:30 am

SymBio Pharmaceuticals Limited announced earnings guidance for the fiscal year ending December 30, 2020. For the year, the company expects Net sales of JPY 3,043 million, Operating loss of JPY 4,592 million, Ordinary loss of JPY 4,656 million, loss of JPY 3,796 million and LPS of JPY 116.13.

Latest news about SymBio Pharmaceuticals Limited

Symbio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2024	05-07	CI
SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	04-18	CI
SymBio Pharmaceuticals Limited amended terms of the transaction	03-17	CI
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss	02-12	MT
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024	02-08	CI
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	02-08	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-08	CI
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand	11-15	MT
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	11-14	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	11-14	CI
SymBio Pharmaceuticals Limited amended terms of the transaction	11-09	CI
SymBio Pharmaceuticals Limited announced that it expects to receive ¥2.208 billion in funding from Evolution Capital Management LLC	23-10-05	CI
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-08-03	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03	CI
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-04-27	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Symbio Pharmaceuticals Signs Cooperative R&D Deal to Investigate Brincidofovir's Efficacy in EBV Diseases	23-04-25	MT
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases	23-04-23	CI
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke	23-03-22	CI
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-02-09	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-08	CI
Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022	22-11-08	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-04	CI
Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022	22-08-04	CI
SymBio Pharmaceuticals Limited announced that it has received ¥675.76 million in funding from CVI Investments, Inc.	22-05-31	CI

Chart SymBio Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

SymBio Pharmaceuticals Limited is a Japan-based pharmaceutical company. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The Company develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The Company manufactures and sells medicines through domestic and foreign pharmaceutical companies. The Company's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SYMBIO PHARMACEUTICALS LIMITED	-26.72%	51.61M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B
PFIZER, INC.	-2.57%	159B

Other Pharmaceuticals